Mark T. Carges
Known title: DirectorCIK: 0001303935
Associated companies
Transaction History
| VEEV | ▲ Buy | Option Exercise | 493 | $0 | 9/1/2026 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 271 | $0 | 6/1/2026 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 271 | $0 | 3/1/2026 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 271 | $0 | 12/1/2025 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 271 | $0 | 9/1/2025 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 357 | $0 | 6/1/2025 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 356 | $0 | 3/1/2025 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 357 | $0 | 12/1/2024 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 357 | $0 | 9/1/2024 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 315 | $0 | 6/1/2024 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 314 | $0 | 3/1/2024 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 315 | $0 | 12/1/2023 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 315 | $0 | 9/1/2023 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 340 | $0 | 6/1/2023 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 339 | $0 | 3/1/2023 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 340 | $0 | 12/1/2022 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 340 | $0 | 9/1/2022 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 205 | $0 | 6/1/2022 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 205 | $0 | 3/1/2022 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 205 | $0 | 12/1/2021 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 205 | $0 | 9/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Veeva Gains Investor Attention Amid R&D Growth and AI Focus
Veeva Systems is drawing investor interest as analysts note strong R&D growth and a positive outlook. The company has secured a major research partner that now uses its software as the default clinical platform, and a recent IQVIA deal expands its market reach. Large institutional investors are also increasing exposure to Veeva as part of an AI software play.
Veeva Gains Investor Attention Amid R&D Growth and AI Focus. Veeva Systems is drawing investor interest as analysts note strong R&D growth and a positive outlook. The company has secured a major research partner that now uses its software as the default clinical platform, and a recent IQVIA deal expands its market reach. Large institutional investors are also increasing exposure to Veeva as part of an AI software play.